Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2017
Price : $35 *
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ISABR Study
- 31 Aug 2018 Biomarkers information updated
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 24 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 1 Jan 2018.